<DOC>
	<DOCNO>NCT01276574</DOCNO>
	<brief_summary>The purpose study determine , whether clinical benefit use fdg-PET/CT ( F-18-fluorodeoxyglucose- positron emission tomography/computed tomography ) compare contrast-enhanced CT primary treatment advance epithelial ovarian cancer ( EOC ) - Objectives - impact preoperative PET/CT compare CT EOC stage definition - compare value preoperative PET/CT , CT laparoscopy intra-abdominal tumour assessment . Laparotomy finding evaluate surgeon histopathologic result serve reference standard . - compare serum marker HE4 ( human epididymis protein 4 ) CA125 ( cancer antigen 125 ) FDG-PET/CT CT treatment response evaluation neoadjuvant chemotherapy primary treatment EOC - Methods - All patient undergo FDG-PET/CT prior surgery , possible neoadjuvant chemotherapy ( NACT ) 4 week completion primary platinum-based chemotherapy . - CA125 HE4 level measure pre-operatively every chemotherapy cycle .</brief_summary>
	<brief_title>Epithelial Ovarian Cancer- Staging Response Chemotherapy Evaluated PET/CT</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>Newly diagnose patient advanced epithelial ovarian , primary peritoneal cancer fallopian tube cancer . age 1879 year inform concent diabetes previous cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PET/CT</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>HE4</keyword>
</DOC>